Q-omics provides the consensus-scored ADAM12 profile across patient tissues and cancer cell-line models. ADAM12 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, ADAM12 is differentially expressed in 15, with the highest sampling consensus in HNSC. Additionally, ADAM12 RNA expression shows 23,336 significant protein co-abundance associations, with the highest sampling consensus in LUAD. Together, these results highlight ACC, HNSC, and LUAD as cancer lineages where ADAM12 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ADAM12 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ADAM12 survival associations across molecular data types. ADAM12 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (6) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ADAM12 RNA expression–survival associations across cancer types. High ADAM12 expression shows unfavorable associations in ACC, UVM, KIRP, MESO, LIHC and LGG. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for ADAM12 RNA expression.
This table summarizes ADAM12 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 2. The strongest signals are observed in HNSC for RNA and PDAC for protein.
This table ranks reproducible tumor–normal expression differences for ADAM12. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ADAM12 shows higher tumor expression in HNSC, BLCA, COAD, STAD, LUAD and KIRC. The HNSC box plot shows higher ADAM12 RNA expression in tumor versus normal tissue (log2 FC = +4.181, t-test p < 0.001).
This table shows molecular features associated with ADAM12 in patient tissues and cancer cell lines. In patient samples, ADAM12 shows the broadest associations at the RNA and protein expression levels, with LUAD recurring as the lineage with the largest associated feature set. In cancer cell lines, ADAM12 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in BONE and LARGE_INTESTINE.
